对复制能力强的和复制能力差的单纯疹病毒1的瘤治疗活性进行比较
Georg Lindner1, Annika Walter1, Clara L Magnus1
1Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Immunology
|March 6, 2024
概括
复制缺陷的简单疹病毒1 (HSV-1) d106S显示出对瘤的瘤性活性比复制能力较强的T-VEC. 然而,T-VEC诱导了更强的免疫反应和免疫细胞死亡,突出了不同的治疗潜力.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 塔利莫基因拉赫帕雷普韦克 (T-VEC),一种瘤性简单疹病毒1 (HSV-1),于2015年被批准用于治疗不可切除的黑色素瘤.
- 病毒复制对于瘤治疗疗效的必要性仍然是一个研究领域.
研究的目的:
- 为了比较复制缺陷的HSV-1 (d106S) 与复制能力强的对应物 (T-VEC) 的瘤解毒活性和免疫反应.
- 调查病毒复制在触发细胞亡和免疫细胞死亡中的作用.
主要方法:
- 在黑色素瘤,头皮状细胞癌和用HSV-1 d106S和T-VEC治疗的冠状腺癌细胞系中MTT代谢活性的比较.
- 评估卡斯巴酶激活 (卡斯巴酶3/7,8和9) 以确定亡诱导.
- 分析受感染细胞蛋白 (ICP) 0到ICP6的比率,干扰素-βmRNA的表达,以及免疫细胞死亡的标志物 (ATP释放,HMGB1诱导).
主要成果:
- 高剂量的HSV-1 d106S显示瘤细胞的死亡速度明显快于T-VEC.
- 这两种病毒都诱导了酶依赖的亡,HSV-1 d106S显示了诱导亡的ICP0与ICP6的比率更高.
- 与HSV-1 d106S.相比,T-VEC引起了更强的先天免疫反应 (增加了干扰素-β) 和更明显的免疫细胞死亡 (更高的ATP释放).
结论:
- 非复制性HSV-1 d106S在多种瘤类型中提供了更强的早期瘤治疗效应.
- 具有复制能力的T-VEC诱导更强大的免疫反应和免疫细胞死亡,可能有助于长期疗效.
- 这些发现表明,对复制缺陷和复制能力强的瘤性HSV-1菌株都有明显的治疗优势.
相关概念视频
Size and Structure of Viral Genomes
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
Viral Replication: Lytic Cycle
Bacteriophages, or phages, are viruses that specifically infect bacteria. Among them, T-even bacteriophages, such as T4, exhibit a well-characterized lytic replication cycle in Escherichia coli (E. coli). This process ensures the rapid proliferation of the virus while ultimately leading to the destruction of the bacterial host.Attachment and DNA InjectionThe infection process begins with the recognition and binding of the T4 phage to the E. coli cell surface. Tail fibers of the phage...
Herpes
Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
Genital Herpes
Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...


